A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults

Inclusion Criteria: * Healthy adult older than 19 years old and younger than 50 years old * A subject who was informed of the purpose, method, and efficacy of the clinical study and signed the written informed consent form Exclusion Criteria: * A subject who participated in other clinical studies within 3 months before screening * A subject who was vaccinated with other vaccines within 4 weeks before screening, or who is expected to receive other vaccination during the clinical study period * A subject with medical history of hypersensitive reactions (e.g. anaphylaxis) to the test drug or its ingredients * A subject who received immunoglobulin or blood-derived materials within 3 months before screening * A subject with immunologic function disorders including congenital or acquired immunodeficiency disorders * A subject who is receiving immunosuppressive therapy or drugs that can affect immunological reaction * A subject with pyrexia of over 38 Celsius degrees on the day of the vaccination with the investigational products * A subject with medical history of Invasive Pneumococcal Disease (IPD) or pneumonia caused by Streptococcus pneumoniae * A subject who was vaccinated with any pneumococcal vaccine before screening * A subject who received the vaccine containing diphtheria toxoid within 6 months before screening (e.g. adult Td vaccine)